V. R. Chernovanova
Research Subjects
V. R. Chernovanova has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- A. L. Kovalenko
Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1
2 shared publications - I. S. Polyakov
Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1; Kuban State Medical University
2 shared publications - Irina Valeryevna Gilevich
Kuban State Medical University
2 shared publications - Vladimir Alekseyevich Porkhanov
Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1; Kuban State Medical University
2 shared publications - A. A. Semenchenko
Kuban State Medical University
1 shared publication - A. B. Mandal
Kuban State Medical University
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- Vol. 11 (4) , 43-51
Assessment of the Effect of Storage Conditions on the Quality of a Biomedical Cell Product Derived from Human Dermal Fibroblasts
Background: The efficacy of cell therapy directly depends on the viability and functional activity of cells in the ready-to-use cell product. The search for optimal storage conditions for a cellular product remains an urgent challenge as there is currently no universally accepted method for ensuring the stability of the final product during storage and transportation, thereby requiring the determination of optimal temperature conditions and storage duration. Objective: To determine the optimal storage conditions for a final biomedical cell product based on a suspension of human dermal fibroblasts to ensure their morphofunctional stability. Materials and methods: The study used a ready-to-use cell product based on cultured human dermal fibroblasts, passage 5. After reaching confluence, the cells were detached from the culture flasks by trypsinization. The resulting cell pellet was resuspended in saline solution and incubated at temperatures of +4 °C, +22 °C and +37 °C for 12, 24 and 36 hours. At the end of the storage period, the number and viability of cells, metabolic activity, endotoxin presence, as well as adhesive and proliferative properties during subsequent culture were evaluated. Results: The study showed that at a temperature of +22 °C, compared with other temperature conditions, fibroblasts demonstrated the highest viability and functional activity. At this temperature, the cells retained their ability to adhere, proliferate, and maintain secretory activity for 12 hours of storage. With an increase in storage duration to 24 and 36 hours, a statistically significant decrease in the cell number, their metabolic and secretory activity, was observed in all experimental groups. Conclusion: Storage of human dermal fibroblasts in suspension at +22 °C for 12 hours ensures the preservation of cell viability, metabolic activity, and morphofunctional properties, making this condition optimal for storage and transportation of fibroblasts as part of ready-to-use cell products.
- 9 November 2026
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- Vol. 11 (4) , 43-51
Open AccessAssessment of the Effect of Storage Conditions on the Quality of a Biomedical Cell Product Derived from Human Dermal Fibroblasts
Background: The efficacy of cell therapy directly depends on the viability and functional activity of cells in the ready-to-use cell product. The search for optimal storage conditions for a cellular product remains an urgent challenge as there is currently no universally accepted method for ensuring the stability of the final product during storage and transportation, thereby requiring the determination of optimal temperature conditions and storage duration. Objective: To determine the optimal storage conditions for a final biomedical cell product based on a suspension of human dermal fibroblasts to ensure their morphofunctional stability. Materials and methods: The study used a ready-to-use cell product based on cultured human dermal fibroblasts, passage 5. After reaching confluence, the cells were detached from the culture flasks by trypsinization. The resulting cell pellet was resuspended in saline solution and incubated at temperatures of +4 °C, +22 °C and +37 °C for 12, 24 and 36 hours. At the end of the storage period, the number and viability of cells, metabolic activity, endotoxin presence, as well as adhesive and proliferative properties during subsequent culture were evaluated. Results: The study showed that at a temperature of +22 °C, compared with other temperature conditions, fibroblasts demonstrated the highest viability and functional activity. At this temperature, the cells retained their ability to adhere, proliferate, and maintain secretory activity for 12 hours of storage. With an increase in storage duration to 24 and 36 hours, a statistically significant decrease in the cell number, their metabolic and secretory activity, was observed in all experimental groups. Conclusion: Storage of human dermal fibroblasts in suspension at +22 °C for 12 hours ensures the preservation of cell viability, metabolic activity, and morphofunctional properties, making this condition optimal for storage and transportation of fibroblasts as part of ready-to-use cell products.
- Open Access
- 22 May 2025
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- Vol. 10 (2) , 78-86
Modern Treatments of Bronchial Fistulas
Background: Bronchial fistulas (BF) are a dangerous complication of thoracic surgery accompanied with a high mortality rate. Long-term conservative treatment of BF is ineffective, and surgery can lead to repeated complications. Although cell therapy is considered a safe and effective method for stimulating regeneration and has found its use in many fields of medicine, its application in thoracic surgery is limited.Objective: To evaluate effectiveness of a cell product (autologous platelet lysate+allogeneic fibroblasts) in enhancing BF healing and to prove its safety.Materials and methods: Our study included 91 patients from thoracic units of the Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1 (Krasnodar, Russian Federation) who were divided into 2 groupes: standard therapy (34 patients) and cell therapy (57 patients).Results: In the group receiving cell therapy, BFs healed in 93% of the patients, with no death cases. In the control group, BFs healed only in 50% of the patients (59% of them, after reoperation), and the overall mortality was 35.3%. During the follow-up, no cancer progression was observed in 47.4% of the main group patients and 20.6% of the controls, proving safety of the cell product and absence of an oncogenic effect.Conclusions: Our findings indicate that the cell product is effective in tissue regeneration compared with the standard therapy. The data on its safety and effectiveness can lay the foundation for future large-scale studies to improve clinical treatment outcomes.
- 22 May 2025
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- Vol. 10 (2) , 78-86
Open AccessModern Treatments of Bronchial Fistulas
Background: Bronchial fistulas (BF) are a dangerous complication of thoracic surgery accompanied with a high mortality rate. Long-term conservative treatment of BF is ineffective, and surgery can lead to repeated complications. Although cell therapy is considered a safe and effective method for stimulating regeneration and has found its use in many fields of medicine, its application in thoracic surgery is limited.Objective: To evaluate effectiveness of a cell product (autologous platelet lysate+allogeneic fibroblasts) in enhancing BF healing and to prove its safety.Materials and methods: Our study included 91 patients from thoracic units of the Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1 (Krasnodar, Russian Federation) who were divided into 2 groupes: standard therapy (34 patients) and cell therapy (57 patients).Results: In the group receiving cell therapy, BFs healed in 93% of the patients, with no death cases. In the control group, BFs healed only in 50% of the patients (59% of them, after reoperation), and the overall mortality was 35.3%. During the follow-up, no cancer progression was observed in 47.4% of the main group patients and 20.6% of the controls, proving safety of the cell product and absence of an oncogenic effect.Conclusions: Our findings indicate that the cell product is effective in tissue regeneration compared with the standard therapy. The data on its safety and effectiveness can lay the foundation for future large-scale studies to improve clinical treatment outcomes.
- Open Access
- 18 August 2023
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 3,p. 105-113
Cell Therapy for Upper Respiratory Tract Fistulas
Fistulas of various etiologies are one of the severe and life-threatening diseases of the upper respiratory tract. The most common cause is bronchial stump failure after pulmonary resection, usually pneumonectomy. The incidence and mortality of this complication is 3 %-4 % and 12.5 %-71.2 %, respectively. Despite the fact that many devices and methods have been described to date, it is usually treated with surgical closure. Standard surgical approaches are associated with significant morbidity and mortality and are not reliably successful. In recent years, cell therapies aimed to stimulate tissue healing rose to prominence and can be considered a potential treatment method. We review current trends in bronchopleural fistula treatment using cell therapy and report cases of the bronchopleural fistula treatment according to the research protocol developed in our clinic. Although clinical experience is quite limited owing to a small number of patients in the most studies, the information on safety and tolerance can help plan future larger trials with innovative methods to further improve clinical results.
- 18 August 2023
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 3,p. 105-113
Open AccessCell Therapy for Upper Respiratory Tract Fistulas
Fistulas of various etiologies are one of the severe and life-threatening diseases of the upper respiratory tract. The most common cause is bronchial stump failure after pulmonary resection, usually pneumonectomy. The incidence and mortality of this complication is 3 %-4 % and 12.5 %-71.2 %, respectively. Despite the fact that many devices and methods have been described to date, it is usually treated with surgical closure. Standard surgical approaches are associated with significant morbidity and mortality and are not reliably successful. In recent years, cell therapies aimed to stimulate tissue healing rose to prominence and can be considered a potential treatment method. We review current trends in bronchopleural fistula treatment using cell therapy and report cases of the bronchopleural fistula treatment according to the research protocol developed in our clinic. Although clinical experience is quite limited owing to a small number of patients in the most studies, the information on safety and tolerance can help plan future larger trials with innovative methods to further improve clinical results.